CDKN1A and melanoma: GILZ signaling, via the inhibition of FOXO3A and its downstream target, the cell cycle inhibitor, cyclin-dependent kinase inhibitor 1 (p21CIP1), antagonizes cell quiescence, induces cell cycle reactivation and tumor development in dormant murine melanoma cells.